Russia registers third-generation vaccine against hepatitis B

Moscow, Aug 19 (Prensa Latina) The Russian Ministry of Health registered a third-generation vaccine against hepatitis B, under the name Sci-B-Vac.

The health agency confirmed to TASS news agency that the exclusive distributor of the vaccine will be Pharmsynthez, one of the pharmaceutical companies of the Russian nanotechnology company Rosnano.

Pharmsynthez General Director Efim Prilezhaev pointed out that researches showed that the use of the Sci-B-Vac vaccine halved the incidence of acute and chronic hepatitis B and hepatocellular carcinoma among those vaccinated, in comparison with other drugs against the disease.

In this regard, the registration of the vaccine can contribute to solve the serious problem of availability of effective and safe vaccines existing today, the scientist noted.

He pointed out that the drug provides longer protection and guarantees the formation of stronger antiviral immunity, since two years after receiving it, the test subjects had 5.5 times more antibodies than those vaccinated with conventional drugs.

Under the company’s plans, the pilot shipment of 80,000 doses of the Sci-B-Vac is scheduled for the end of 2022.

The need for the new vaccine in the Russian pharmaceutical market could be more than 300,000 doses a year, according to the Health Ministry’s estimates.